Search Results

You are looking at 61 - 70 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Myeloid Growth Factors

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland

Overview Neutropenia (< 500 neutrophils/mcL or < 1000 neutrophils/mcL and a predicted decline to < 500/mcL over the next 48 hours) and resulting febrile neutropenia (≥ 38.3°C orally or ≥ 38.0°C over 1 hour) can be induced by myelosuppressive

Full access

Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works for Defined Outcomes in Defined Populations, but Must Be Used Wisely

Eric J. Bow

neutropenia and fever] . Rev Esp Quimioter 2001 ; 14 : 75 – 83 . 3 Hughes WT Armstrong D Bodey GP . 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer . Clin Infect Dis 2002 ; 34 : 730 – 751 . 4

Full access

HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting

Jeffrey Scott, Dean Slack, Lindsay Gingras, Marc Chioda, and Huan Huang

INTRODUCTION : Myelosuppressive hematologic adverse events (HAEs; anemia, neutropenia, thrombocytopenia) are common complications of cytotoxic chemotherapy, a cornerstone of treatment for extensive-stage small cell lung cancer (ES-SCLC). This

Full access

CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

Yazan Madanat, Michael R. Savona, Mikkael A. Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Shyamala Navada, Rami S. Komrokji, and Amer M. Zeidan

imetelstat in various subgroups (Table). In 8-wk TI responders, median Hb rise in the TI periods was 3.6 vs 0.8 g/dL with placebo; the increase was seen in responders within ≤4 wk of treatment. Common AEs of grade 3/4 thrombocytopenia (62%) and neutropenia

Full access

CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population

Yiseiry Perez Melendez, A Mahmoud, R Caddell, R Nelson, L Sokol, B Shah, and H Saeed

dose of 2500 units/m2/dose IV on Day 8. Cycles repeated every 28 days until disease progression, transplant, or excessive toxicity development. Peg-filgrastim or filgrastimgiven for neutropenia. Antimicrobial prophylaxis was with acyclovir

Full access

CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia

Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, and Pankit Vachhani

in those who developed TLS. No significant association was found between Ven ramp up and TLS incidence. 42(37.8%) had known infections prior to starting HMA+Ven. 41 patients (36.9%) were diagnosed with febrile neutropenia; 36 (32.4%) had confirmed

Full access

Prevention and Treatment of Cancer-Related Infections

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma, and Dorothy A. Shead

Infectious diseases are important causes of morbidity and mortality in patients with cancer. In certain instances, the malignancy itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized for many decades as a major

Full access

New Biosimilar Approvals for Myeloid Growth Factors and Anemia

Gary H. Lyman

patients with breast cancer showed that the biosimilar filgrastim was equally effective as the reference product in the prevention of neutropenia in patients receiving myelosuppressive chemotherapy. 3 Filgrastim-sndz was subsequently approved for the

Full access

CLO24-081: Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck–Biweekly Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (TPFL) Versus Triweekly TPF: Response Assessment and Translation Into Survival Benefit

Sreevalli Anantharamu, A Sreevalli, Linu Abraham Jacob, Lokanatha Dasappa, Suresh Babu MC, Iokesh KN, Rudresha AH, R. Lakkavalli Krishnappa, and Saldanha Saldanha

%. Among the toxicities grade 3/4 neutropenia was seen in 23.3% vs 41.7% ( P =.05), febrile neutropenia in 6.7% vs 20% ( P =.031). Grade 3/4 mucositis was seen in 5% vs 23.3%( P =.007), grade 3/4 diarrhea in 1.7% vs 10% ( P =.027). Treatment delay and inter

Full access

CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang

: Panobinostat is associated with a substantially higher odds of anemia, thrombocytopenia, fatigue and diarrhea. However, it has a 75% lower risk of neutropenia and 10% lower risk of grade 3 and 4 complications. Figure 1 Odds ratio of grade 3 and grade 4